Umeclidinium/vilanterol

Drug Profile

Umeclidinium/vilanterol

Alternative Names: '444+'719; '719/VI; 573719/642444; 642444/573719; Anoro Ellipta; GSK 573719/GW 642444; Laventair; UMEC/VI; Vilanterol/GSK 573719; Vilanterol/umeclidinium

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline
  • Class Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethanolamines; Ethers; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Jul 2016 GlaxoSmithKline does not wish to exercise the option to take a licence to any additional patents and option agreement for Ellipta® products under the worldwide non-exclusive agreement with Vectura
  • 18 May 2016 Efficacy data from a phase III trial (DB2116960) in Chronic obstructive pulmonary disease released by GlaxoSmithKline
  • 08 Jan 2016 Theravance is now called Innoviva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top